Drug trial tests treatment for rare skin cancer
NCT ID NCT05442554
Summary
This study tested brentuximab vedotin in Chinese adults with CD30-positive cutaneous T-cell lymphoma, a rare type of skin cancer. Ten participants received the drug through an IV every 3 weeks for up to 16 cycles. Researchers monitored how well the treatment worked and tracked side effects over time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Huashan Hospital, Fudan University
Shanghai, Shanghai Municipality, 200040, China
-
Peking University First Hospital
Beijing, Beijing Municipality, 100034, China
-
Peking University Third Hospital
Beijing, Beijing Municipality, 100191, China
-
West China Hospital, Sichuan University
Chengdu, Sichuan, 610041, China
Conditions
Explore the condition pages connected to this study.